Our publications
Comparison of Immuno-PET of CD138 and PET imaging with 64CuCl2 and 18F-FDG in a preclinical syngeneic model of multiple myeloma. Bailly C, Gouard S, Lacombe M, Remaud-Le Saëc P, Chalopin B, Bourgeois M, Chouin N, Tripier R, Halime Z, Haddad F, Faivre-Chauvet A, Kraeber-Bodéré F, Chérel M, Bodet-Milin C, Oncotarget 2018, 9:9061-9072
Pretargeting in the context of theranostics and companion diagnostics in nuclear oncology. Barbet J. Clin Transl Imaging. (2018) 1-9.
Translational molecular imaging in exocrine pancreatic cancer. Cornelissen B, Knight JC, Mukherjee S, Evangelista L, Xavier C, Caobelli F, Del Vecchio S, Rbah-Vidal L, Barbet J, de Jong M, van Leeuwen FWB. Eur J Nucl Med Mol Imaging. (2018)45, 2442-2455.
Interim PET analysis in first line therapy of multiple myeloma: Prognostic value of ΔSUVmax in the FDG-avid patients of the IMAJEM study, Bailly C, Carlier T, Jamet B, Eugene T, Touzeau C, Attal M, Hulin C, Facon T, Leleu X, Perrot A, Garderet L, Macro M, Caillot D, Moreau P, Kraeber-Bodere F, Bodet-Milin C , Clin Cancer Res. 2018, 24:5219-5224 IF 10.199 JIF 94.820
PET Imaging criteria in Myeloma, Kraeber-Bodéré F, 7th international workshop on PET in lymphoma and myeloma PIM, Menton, France, October 5-6 2018 (invited)
PET Imaging criteria in Myeloma, Bodet-Milin C, 7th international workshop on PET in lymphoma and myeloma PIM, Menton, France, October 5-6 2018 (invited)
Efficacy of Astatine-211 radioimmunotherapy of Multiple Myeloma using an anti-mCD138 monoclonal antibody in a syngeneic murine model (OP-508). Gouard S, Chalopin B, Maurel C, Guérard F, Navarro L, Gestin JF, Chouin N, Haddad F, Alliot C, Kraeber-Bodéré F, Davodeau F, Chérel M . EANM’18 31th Annual congress of the European Association of Nuclear Medicine, Dusseldorf, Germany, oct 13-17 2018
Biodistribution, Imaging and Metabolism Studies of 64-Copper Radiolabelled Monoclonal Antibody: Comparison of DOTA and TE1PA Chelating Agents in a Murine Model of Multiple Myeloma (OP-375). Navarro AS, Le Bihan T, Le Saëc P, Gouard S, Le Bris N, Bailly C, Saï-Maurel C, Chalopin B, Gestin JF, Chérel M, Tripier R, Faivre-Chauvet A. EANM’18 31th Annual congress of the European Association of Nuclear Medicine, Dusseldorf, Germany, oct 13-17 2018
PET Imaging of Multiple Myeloma: Comparison of 89Zr- and 64Cu-labeled anti-CD138 Conjugates to 64CuCl2 and 18F-FDG in a Preclinical Syngeneic Model (OP-040). Bailly C, Gouard S, Chalopin B, Carlier T, Maurel C, Remaud-Le Saëc P, Bourgeois M, Chouin N, Tripier R, Haddad F, Faivre-Chauvet A, Kraeber-Bodere F, Bodet-Milin C, Cherel M . EANM’18 31th Annual congress of the European Association of Nuclear Medicine, Dusseldorf, Germany, oct 13-17 2018
Preliminary results of 68Ga-PSMA PET/CT prospective study in prostate cancer occult recurrence patients: diagnostic performance and impact on therapeutic decision-making (OP-042). Rousseau C, Le Thiec M, Ferrer L, Rusu D, Rauscher A, Maucherat B, Frindel M, Baumgartner P, Fleury V, Denis V, Varmenot N, Debeaupuis E, Campion L, Kraeber-Bodéré F . EANM’18 31th Annual congress of the European Association of Nuclear Medicine, Dusseldorf, Germany, oct 13-17 2018
Why should we take care about occupational dosimetric impact when routine use of gallium-68 in nuclear medicine? A preliminary study (OP-238). Varmenot N, Ferrer L, Frindel M, Rauscher A, Baumgartner P, Delaunay F, Mathey A, Pitel C, Zulian H, Kraeber-Bodéré F, Denis A, Rousseau C . EANM’18 31th Annual congress of the European Association of Nuclear Medicine, Dusseldorf, Germany, oct 13-17 2018